Primary navigation

    Ibrance

    Drug - IBRANCE™ (palbociclib capsules) [Pfizer]

    May 2016

    Therapeutic area - Oncology

    Approval criteria

    • Patient has a diagnosis of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer AND
    • Ibrance treatment will be in combination with letrozole as initial endocrine based therapy in postmenopausal women OR
    • In combination with fulvestrant in women with disease progression following endocrine therapy

    Quantity limit

    21 capsules every 28 days

    Background information

    IBRANCE is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top